Chondrogenesis mediates progression of ankylosing spondylitis through heterotopic ossification

[1]  Y. Mishina,et al.  Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing , 2020, Nature Communications.

[2]  Xinzhong Dong,et al.  Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice , 2019, Nature Communications.

[3]  X. Weng,et al.  Ankylosing spondylitis: etiology, pathogenesis, and treatments , 2019, Bone Research.

[4]  W. Lems,et al.  Long‐Term Treatment With TNF‐Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  Xinzhong Dong,et al.  Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain , 2019, The Journal of clinical investigation.

[6]  R. Lories.  Advances in understanding the pathophysiology of spondyloarthritis. , 2018, Best practice & research. Clinical rheumatology.

[7]  R. Landewé,et al.  Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort , 2018, The Journal of Rheumatology.

[8]  Ping Yang,et al.  Inhibition of overactive TGF-β attenuates progression of heterotopic ossification in mice , 2018, Nature Communications.

[9]  M. Dougados,et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2017, Annals of the rheumatic diseases.

[10]  A. Deodhar,et al.  Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. , 2017, Seminars in arthritis and rheumatism.

[11]  G. Louie,et al.  Osteoporosis Management in Ankylosing Spondylitis , 2016, Current Treatment Options in Rheumatology.

[12]  U. Syrbe,et al.  Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS) , 2015, Annals of the rheumatic diseases.

[13]  W. Grayson.  Faculty Opinions recommendation of PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. , 2015 .

[14]  L. Duong,et al.  PDGF-BB secreted by preosteoclasts induces CD31hiEmcnhi vessel subtype in coupling osteogenesis , 2014, Nature Medicine.

[15]  G. Macfarlane,et al.  Global prevalence of ankylosing spondylitis. , 2014, Rheumatology.

[16]  R. Adams,et al.  Endothelial Notch activity promotes angiogenesis and osteogenesis in bone , 2014, Nature.

[17]  R. Adams,et al.  Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone , 2014, Nature.

[18]  J. Lotz,et al.  Innervation of pathologies in the lumbar vertebral end plate and intervertebral disc. , 2014, The spine journal : official journal of the North American Spine Society.

[19]  Janet L. Crane,et al.  Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling. , 2014, The Journal of clinical investigation.

[20]  D. Poddubnyy,et al.  Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis – a five-year update , 2013, Expert opinion on biological therapy.

[21]  L. Riley,et al.  Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis , 2013, Nature Medicine.

[22]  B. Hallgrímsson,et al.  Heterotopic mineralization (ossification or calcification) in tendinopathy or following surgical tendon trauma , 2012, International journal of experimental pathology.

[23]  D. Medici,et al.  The role of endothelial‐mesenchymal transition in heterotopic ossification , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  A. Taylan,et al.  Evaluation of the T helper 17 axis in ankylosing spondylitis , 2012, Rheumatology International.

[25]  D. M. van der Heijde,et al.  Health and imaging outcomes in axial spondyloarthritis , 2016 .

[26]  S. Hajdu,et al.  Elevated transforming growth factor-beta 1 (TGF-β1) levels in human fracture healing☆ , 2011, Injury.

[27]  M. Magrey,et al.  Osteoporosis in Ankylosing Spondylitis , 2010, Current rheumatology reports.

[28]  G. Schett,et al.  Can we stop progression of ankylosing spondylitis? , 2010, Best practice & research. Clinical rheumatology.

[29]  W. Maksymowych.  Disease modification in ankylosing spondylitis , 2010, Nature Reviews Rheumatology.

[30]  Yi Tang,et al.  TGF-β1-induced Migration of Bone Mesenchymal Stem Cells Couples Bone Resorption and Formation , 2009, Nature Medicine.

[31]  J. David,et al.  Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints , 2009, Annals of the rheumatic diseases.

[32]  D. M. van der Heijde,et al.  Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. , 2008, Arthritis and rheumatism.

[33]  J. Braun,et al.  The relationship between inflammation and new bone formation in patients with ankylosing spondylitis , 2008, Arthritis research & therapy.

[34]  D. M. van der Heijde,et al.  Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[35]  D. M. van der Heijde,et al.  Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. , 2008, Arthritis and rheumatism.

[36]  A. Deodhar,et al.  Osteoporosis and vertebral fractures in ankylosing spondylitis , 2007, Current opinion in rheumatology.

[37]  D. Wendling,et al.  Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis , 2007, Current opinion in rheumatology.

[38]  P. D. Kraan,et al.  TGF-β and osteoarthritis , 2007 .

[39]  F. Luyten,et al.  Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. , 2007, Arthritis and rheumatism.

[40]  H. Stein,et al.  Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. , 2006, Arthritis and rheumatism.

[41]  H. Stein,et al.  Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. , 2006, Arthritis and rheumatism.

[42]  J. Braun,et al.  Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. , 2005, Arthritis and rheumatism.

[43]  J. Braun,et al.  Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. , 2005, Rheumatology.

[44]  J. Braun,et al.  Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept , 2005, Annals of the rheumatic diseases.

[45]  J. Braun,et al.  Treatment of active ankylosing spondylitis with pamidronate. , 2003, Rheumatology.

[46]  L. Espinoza,et al.  A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et al. , 2003, Arthritis and rheumatism.

[47]  Justin P. Annes,et al.  Making sense of latent TGFβ activation , 2003, Journal of Cell Science.

[48]  H. V. Kuppevelt,et al.  Neurogenic heterotopic ossification in spinal cord injury , 2002, Spinal Cord.

[49]  M. Zasloff,et al.  Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. , 2002, The New England journal of medicine.

[50]  E. Bywaters,et al.  Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. , 2000, Arthritis and rheumatism.

[51]  M. Muenke,et al.  Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. , 1996, The New England journal of medicine.

[52]  G. Finkel,et al.  The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. , 1993, The Journal of bone and joint surgery. American volume.

[53]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[54]  H. Rubinstein.  Osteoporosis in ankylosing spondylitis. , 1991, British journal of rheumatology.

[55]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[56]  R D Sturrock,et al.  Ankylosing spondylitis and HL-A 27. , 1973, Lancet.

[57]  L. Idolazzi,et al.  Bisphosphonates vs infliximab in ankylosing spondylitis treatment. , 2014, Rheumatology.

[58]  I. Batmaz,et al.  Prevalence of osteoporosis and vertebral fractures and related factors in patients with ankylosing spondylitis. , 2014, Chinese medical journal.

[59]  温春毅,et al.  Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis , 2013 .

[60]  R. Kalluri,et al.  Conversion of vascular endothelial cells into multipotent stem-like cells , 2010, Nature Medicine.

[61]  W. B. van den Berg,et al.  TGF-beta and osteoarthritis. , 2007, Osteoarthritis and cartilage.

[62]  AN Endochondral.  The Histopathology of Fibrodysplasia Ossificans Progressiva , 2006 .

[63]  D. Rifkin,et al.  Making sense of latent TGFbeta activation. , 2003, Journal of cell science.

[64]  G. Jhangri,et al.  Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. , 2001, The Journal of rheumatology.

[65]  A. Schuerwegh,et al.  Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. , 2001, Clinical and experimental rheumatology.